Due to NRP-1 overexpression on many types of cancer cells ([16] and papers cited therein, [17]) as well as the relatively well-known mechanisms of the formation and action of the VEGF-A165/NRP-1 complex, the design of novel compounds that can block the formation of this complex is a promising direction in the search for anti-angiogenic and anti-cancer drugs [12,14,18,19]. This evidence concerns the gene NRP1 and cancer.